Will the FDA approve VERVE-102?
As of Tue, 20 Oct 2026 11:11:57 UTC, Kalshi traders price Before 2035 (84.0%), Before 2034 (79.0%), Before 2033 (76.0%). The market has $2K in volume and closes on Mon, 01 Jan 2035.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Before 2035 | 84.0% | 84.0¢ | 16.0¢ |
| Before 2034 | 79.0% | 79.0¢ | 21.0¢ |
| Before 2033 | 76.0% | 76.0¢ | 24.0¢ |
| Before 2032 | 73.0% | 73.0¢ | 27.0¢ |
| Before 2031 | 66.0% | 66.0¢ | 34.0¢ |
| Before 2030 | 54.0% | 54.0¢ | 46.0¢ |
Market details
- Venue: Kalshi
- Volume: $2K
- Liquidity: $2K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for Before 2035:
If the FDA approves VERVE-102 for marketing before Jan 1, 2035, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete…
Sources
Related markets
- How many launches will SpaceX have in September?
- Tesla Optimus released this year?
- How many launches will SpaceX have this year?
- How many launches will SpaceX have in October?
- When will any company achieve AGI?
- When will Apple release the iPhone 18?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.